Last updated on December 2018

Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate


Brief description of study

The purpose of this study is to provide access to palbociclib in Mexico and in selected Latin American countries before it becomes commercially available to patients with HR positive/HER2-negative ABC who are appropriate candidates for letrozole therapy.

Clinical Study Identifier: NCT02600923

Contact Investigators or Research Sites near you

Start Over

Pfizer CT.gov Call Center

Sanatorio Guemes
Caba, Argentina
  Connect »

Pfizer CT.gov Call Center

Hospital Italiano de Buenos Aires
Caba, Argentina
  Connect »

Pfizer CT.gov Call Center

Hospital Britanico de Buenos Aires
Caba, Argentina
  Connect »

Pfizer CT.gov Call Center

Instituto Medico Especializado Alexander Fleming
Caba, Argentina
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.